Overview
RNA market data
Price History
RNA price chart · 1M
- O
- 13.79
- H
- 14.06
- L
- 13.70
- C
- 13.95
- Vol
- 2,733.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $13.79
- Previous Close
- $13.82
- Day High
- $14.06
- Day Low
- $13.70
- 52 Week High
- $14.07
- 52 Week Low
- $11.13
- 7 Day Return
- +3.56%
- 30 Day Return
- +21.09%
- 90 Day Return
- +7.39%
- 1 Year Return
- +7.39%
- Daily Notional Volume
- $38.1K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.89 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.07 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -172.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $11.13 – $73.06 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $210.9M · P/B 0.76 · P/S 5.51.
Company News
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price TargetBenzinga · Aug 14, 2026, 5:27 PM
8-K filing — Atrium Therapeutics, Inc. (RNA)SEC EDGAR · Aug 13, 2026, 8:50 PM
Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M EstimateBenzinga · Aug 13, 2026, 8:49 PM
Atrium Therapeutics Announces $15M Milestone Payment From Bristol Myers Squibb On Delivery Of Second Lead Compound In Undisclosed Cardiology IndicationBenzinga · Aug 13, 2026, 12:05 PM
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For ThursdayBenzinga · Aug 6, 2026, 2:12 PM
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25Benzinga · Aug 6, 2026, 11:12 AM
Atrium Therapeutics Says FDA Clears IND Application Allowing It To Move Forward With Corventis Phase 1/2 Clinical Trial To Evaluate ATR 1072 For Treatment Of PRKAG2 SyndromeBenzinga · Jul 14, 2026, 10:33 AM
Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25Benzinga · Jun 18, 2026, 12:55 PM